IN THE NEWS

Eiger to Present at Jefferies 2019 London Healthcare Conference

November 15th, 2019|

Eiger to Present at Jefferies 2019 London Healthcare Conference PALO ALTO, Calif. – November 15, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Jefferies 2019 London Healthcare Conference on November 20, 2019 from 4:00-4:35 PM GMT in London. A live webcast of the presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the [...]

Eiger Announces Peginterferon Lambda – Lonafarnib Combination Interim Results

November 12th, 2019|

Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019 53% of Patients Achieve Undetectable or BLOQ HDV RNA at Week 24 Median Decline of HDV RNA: -3.4 Log at Week 24 95% of Patients Achieve > 2 Log Decline in HDV RNA at Week 24 PALO ALTO, Calif., November 12, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and [...]

Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

November 7th, 2019|

Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update Successful Pre-NDA and Pre-MAA Meetings for Progeria & Progeroid Laminopathies Positive Phase 2 LIFT Lambda Combo Data as Late-Breaker at AASLD First-Ever Phase 3 HDV International D-LIVR Study Enrolling and Dosing Strong Balance Sheet with $109.9M in Cash & Investments PALO ALTO, Calif., November 7, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today [...]